Home › Compare › FDCFF vs ABBV
FDCFF yields 6849.32% · ABBV yields 3.06%● Live data
📍 FDCFF pulled ahead of the other in Year 1
Combined, FDCFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FDCFF + ABBV for your $10,000?
Forum Energy Metals Corp. engages in the evaluation, acquisition, exploration, and development of natural resource properties in Canada and the United States. The company explores for energy metals, including copper, cobalt, uranium, palladium, nickel, platinum, and gold deposits. It holds 100% interests in the Fir Island uranium project covering an area of 20,463; the Janice Lake copper-silver project that covers an area of 39,943 hectares; the Love Lake nickel-copper-palladium-platinum project that covers an area of 32,135 hectares; the Grease River project covering an area of 10,528 hectares; the Wollaston project covering an area of 11,067 hectares; the Highlands project; the Glennie project; the Highrock uranium project; the Still Nickel project; and the Maurice Point uranium project that covers an area of 6,295 hectors located in Saskatchewan. It also holds a 65% interest in the Costigan uranium project; 75% interest in the Clearwater uranium project; 40% interest in the Henday uranium project; and 39.43% interest in the NW Athabasca located in Saskatchewan. In addition, the company also holds 100% interests in the Quartz Gulch property consist of 127 claims covering an area of 10.65 square kilometers located in Idaho; and 100% interests in the Nunavut Uranium project consist of 40 claims covering an area of 97,433 hectares located on the northeast of the Thelon Basin in Nunavut Territory. The company was formerly known as Forum Uranium Corp. and changed its name to Forum Energy Metals Corp. in February 2018. Forum Energy Metals Corp. was incorporated in 1987 and is headquartered in Vancouver, Canada.
Full FDCFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.